📊 August’s Top 3 on DRUGDOCS®
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
September 9, 2026 at 3:59 PM
📊 August’s Top 3 on DRUGDOCS®
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
Friday reminder that laughter can be the best medicine.
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
August 28, 2026 at 2:51 PM
Friday reminder that laughter can be the best medicine.
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
🔬 August 18 is #WorldBreastCancerResearchDay.
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
August 18, 2026 at 2:25 PM
🔬 August 18 is #WorldBreastCancerResearchDay.
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
📊 July’s Top 3 on DRUGDOCS®
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
August 11, 2026 at 2:20 PM
📊 July’s Top 3 on DRUGDOCS®
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
Today is #WorldHepatitisDay.
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
July 28, 2026 at 7:47 PM
Today is #WorldHepatitisDay.
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
📊 June’s Top 3 on DRUGDOCS®
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
July 24, 2026 at 1:47 PM
📊 June’s Top 3 on DRUGDOCS®
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
🎆 Happy Fourth of July!
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
July 4, 2026 at 3:07 PM
🎆 Happy Fourth of July!
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
📊 Clinical evidence is strongest when trial populations reflect the patients who may ultimately use a therapy.
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
10-12 A design for life
This month's PharmaTimes champions the human touch in healthcare, exploring diversity in clinical trials and the role of AI. Plus health comms, probiotics, medicine governance, GLP-1s, and the Clinica...
magazine.pharmatimes.com
June 29, 2026 at 3:00 PM
📊 Clinical evidence is strongest when trial populations reflect the patients who may ultimately use a therapy.
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
💉 Vaccine innovation in focus:
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
Drugmaker Merck said on Thursday the U.S. health regulator has approved an expanded use of its pneumococcal vaccine for children and teenagers who face a higher risk of catching the bacterial diseas...
www.reuters.com
June 24, 2026 at 2:31 PM
💉 Vaccine innovation in focus:
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
💉📉 Retatrutide moves one step closer to approval.
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
Trial of next-gen weight-loss drug retatrutide shows users lose almost a third of their body weight
While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors
www.scientificamerican.com
June 12, 2026 at 2:38 PM
💉📉 Retatrutide moves one step closer to approval.
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
🧠📊 AI doesn't fix weak data—it amplifies it.
A new article explores why high-quality real-world evidence depends on strong data foundations, expert review, and rigorous validation.
Trustworthy evidence starts with trustworthy data.
📖 Read more below.
#DrugDocs #RWE #AI
A new article explores why high-quality real-world evidence depends on strong data foundations, expert review, and rigorous validation.
Trustworthy evidence starts with trustworthy data.
📖 Read more below.
#DrugDocs #RWE #AI
Real-World Evidence in the AI Era: What You Can Unlock Depends on What You Build On
Written by Guy Amster, Senior Principal Machine Learning Engineer, Flatiron Health | The differentiator isn't algorithms; it's data quality. Discover the two critical bottlenecks in oncology RWE and h...
www.fiercepharma.com
June 10, 2026 at 2:25 PM
📊 Top 3 searched drugs on DRUGDOCS® in May:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
June 8, 2026 at 3:21 PM
📊 Top 3 searched drugs on DRUGDOCS® in May:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
Pride reminds us that dignity should never depend on who someone is, who they love, or how they identify.
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
June 1, 2026 at 6:23 PM
Pride reminds us that dignity should never depend on who someone is, who they love, or how they identify.
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
On this #MemorialDay, we at DRUGDOCS, take a moment to honor the brave men and women who made the ultimate sacrifice. Their courage and service will always be remembered.
May 25, 2026 at 8:55 PM
On this #MemorialDay, we at DRUGDOCS, take a moment to honor the brave men and women who made the ultimate sacrifice. Their courage and service will always be remembered.
🧠 The FDA recently announced new support for studies involving psilocybin, methylone, and noribogaine-based therapies for depression, PTSD, and alcohol use disorder.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
On April 18, President Trump issued an Executive Order directing the U.S. Department of Health and Human Services (HHS) to accelerate access to treatments for patients with serious mental illness, inc...
www.fda.gov
May 19, 2026 at 6:56 PM
🧠 The FDA recently announced new support for studies involving psilocybin, methylone, and noribogaine-based therapies for depression, PTSD, and alcohol use disorder.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.
📊 Top 3 searched on DRUGDOCS® in April
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Nereus® – Prevention of motion-induced vomiting
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Epilepsy #Seizure #Ophthalmology #Glaucoma #MotionSickness
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Nereus® – Prevention of motion-induced vomiting
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Epilepsy #Seizure #Ophthalmology #Glaucoma #MotionSickness
May 5, 2026 at 5:06 PM
📊 Top 3 searched on DRUGDOCS® in April
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Nereus® – Prevention of motion-induced vomiting
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Epilepsy #Seizure #Ophthalmology #Glaucoma #MotionSickness
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Nereus® – Prevention of motion-induced vomiting
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Epilepsy #Seizure #Ophthalmology #Glaucoma #MotionSickness
🚀💊 PharmaTimes has recently highlighted 15 years of pharma breakthroughs: mRNA, CAR-T, GLP-1s—shifting care toward precision, prevention, and even cures.
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
22-23 PHARMA - Fast and the curious
This month: the NHS as a dystopian game of Tetris, the GLP-1 explosion and its impact on future meds, plus deep dives into AI in pharma, reproductive health, and Trump’s healthcare influence. Also, co...
magazine.pharmatimes.com
May 1, 2026 at 2:56 PM
🚀💊 PharmaTimes has recently highlighted 15 years of pharma breakthroughs: mRNA, CAR-T, GLP-1s—shifting care toward precision, prevention, and even cures.
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
💊📊 Late-stage trial results
Daraxonrasib doubled median overall survival vs. chemotherapy (13.2 vs. 6.7 months) in pancreatic cancer.
Targeting RAS mutations in >90% of cases—potentially practice-changing data.
📖 Read the article here: www.reuters.com/business/hea...
#Oncology #DRUGDOCS
Daraxonrasib doubled median overall survival vs. chemotherapy (13.2 vs. 6.7 months) in pancreatic cancer.
Targeting RAS mutations in >90% of cases—potentially practice-changing data.
📖 Read the article here: www.reuters.com/business/hea...
#Oncology #DRUGDOCS
Revolution Medicines' experimental cancer pill boosts survival in late-stage study
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live nearly twice as long as those treated with chemotherapy in a keenly anticipated late-stage trial, sending its ...
www.reuters.com
April 27, 2026 at 3:23 PM
💊📊 Late-stage trial results
Daraxonrasib doubled median overall survival vs. chemotherapy (13.2 vs. 6.7 months) in pancreatic cancer.
Targeting RAS mutations in >90% of cases—potentially practice-changing data.
📖 Read the article here: www.reuters.com/business/hea...
#Oncology #DRUGDOCS
Daraxonrasib doubled median overall survival vs. chemotherapy (13.2 vs. 6.7 months) in pancreatic cancer.
Targeting RAS mutations in >90% of cases—potentially practice-changing data.
📖 Read the article here: www.reuters.com/business/hea...
#Oncology #DRUGDOCS
📊 Top 3 drugs searched on DRUGDOCS® in March:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Esbriet® – Antifibrotic agent for idiopathic pulmonary fibrosis
3️⃣ Erleada® – Prostate cancer therapy
Explore the clinical evidence: drugdocs.com
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Esbriet® – Antifibrotic agent for idiopathic pulmonary fibrosis
3️⃣ Erleada® – Prostate cancer therapy
Explore the clinical evidence: drugdocs.com
April 8, 2026 at 8:17 PM
📊 Top 3 drugs searched on DRUGDOCS® in March:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Esbriet® – Antifibrotic agent for idiopathic pulmonary fibrosis
3️⃣ Erleada® – Prostate cancer therapy
Explore the clinical evidence: drugdocs.com
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Esbriet® – Antifibrotic agent for idiopathic pulmonary fibrosis
3️⃣ Erleada® – Prostate cancer therapy
Explore the clinical evidence: drugdocs.com
🏀💊 March Madness, pharma edition.
The #FierceMadness Drug Name Tournament is down to the Final 4. Dawnzera • Rhapsido • Tyngolza • Modeyso
Reply with your winner below👇
Fun names, but serious science behind them. Explore the clinical evidence behind these drugs on DRUGDOCS: drugdocs.com
The #FierceMadness Drug Name Tournament is down to the Final 4. Dawnzera • Rhapsido • Tyngolza • Modeyso
Reply with your winner below👇
Fun names, but serious science behind them. Explore the clinical evidence behind these drugs on DRUGDOCS: drugdocs.com
April 2, 2026 at 6:16 PM
🏀💊 March Madness, pharma edition.
The #FierceMadness Drug Name Tournament is down to the Final 4. Dawnzera • Rhapsido • Tyngolza • Modeyso
Reply with your winner below👇
Fun names, but serious science behind them. Explore the clinical evidence behind these drugs on DRUGDOCS: drugdocs.com
The #FierceMadness Drug Name Tournament is down to the Final 4. Dawnzera • Rhapsido • Tyngolza • Modeyso
Reply with your winner below👇
Fun names, but serious science behind them. Explore the clinical evidence behind these drugs on DRUGDOCS: drugdocs.com
🧠 New research shows stress-responsive neurons may trigger immune activity that worsens eczema. Understanding this link could help guide more targeted treatments. Read more below.
💊 Find the clinical evidence for current eczema treatment options at DRUGDOCS®: drugdocs.com/search/atopi...
💊 Find the clinical evidence for current eczema treatment options at DRUGDOCS®: drugdocs.com/search/atopi...
A sympathetic-eosinophil axis orchestrates psychological stress to exacerbate skin inflammation
Psychological stress is believed to exacerbate dermatitis, yet the neurobiological mechanisms linking stress to immune processes remain elusive. We identified a subset of prodynorphin-positive (Pdyn+)...
www.science.org
March 31, 2026 at 6:39 PM
🧠 New research shows stress-responsive neurons may trigger immune activity that worsens eczema. Understanding this link could help guide more targeted treatments. Read more below.
💊 Find the clinical evidence for current eczema treatment options at DRUGDOCS®: drugdocs.com/search/atopi...
💊 Find the clinical evidence for current eczema treatment options at DRUGDOCS®: drugdocs.com/search/atopi...
🌍 Climate change impacts kidney health.
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
2026 campaign - World Kidney Day 2026
World Kidney Day – 12 March 2026 Kidney Health For All – Caring for People, Protecting the Planet Are Your Kidneys OK? Take this quiz! Kidney Health for All Caring for People, Protecting the Planet Ch...
www.worldkidneyday.org
March 12, 2026 at 3:44 PM
🌍 Climate change impacts kidney health.
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
📊 Top 3 drugs searched on DRUGDOCS® in February:
1️⃣ TNKase® – Stroke and heart attack thrombolytic
2️⃣ Zolymbus™ – Glaucoma ophthalmic gel
3️⃣ Aristada® – Injectable schizophrenia therapy
Explore the evidence: drugdocs.com
#DrugDocs #StrokeCare #Glaucoma #MentalHealth #Pharma
1️⃣ TNKase® – Stroke and heart attack thrombolytic
2️⃣ Zolymbus™ – Glaucoma ophthalmic gel
3️⃣ Aristada® – Injectable schizophrenia therapy
Explore the evidence: drugdocs.com
#DrugDocs #StrokeCare #Glaucoma #MentalHealth #Pharma
March 9, 2026 at 3:56 PM
📊 Top 3 drugs searched on DRUGDOCS® in February:
1️⃣ TNKase® – Stroke and heart attack thrombolytic
2️⃣ Zolymbus™ – Glaucoma ophthalmic gel
3️⃣ Aristada® – Injectable schizophrenia therapy
Explore the evidence: drugdocs.com
#DrugDocs #StrokeCare #Glaucoma #MentalHealth #Pharma
1️⃣ TNKase® – Stroke and heart attack thrombolytic
2️⃣ Zolymbus™ – Glaucoma ophthalmic gel
3️⃣ Aristada® – Injectable schizophrenia therapy
Explore the evidence: drugdocs.com
#DrugDocs #StrokeCare #Glaucoma #MentalHealth #Pharma
🌍 World Obesity Day highlights that 4 billion people may be living with overweight or obesity by 2035.
Addressing obesity requires prevention, equitable care, and evidence-based treatment.
Explore the clinical evidence behind approved obesity therapies on DRUGDOCS®: drugdocs.com
Addressing obesity requires prevention, equitable care, and evidence-based treatment.
Explore the clinical evidence behind approved obesity therapies on DRUGDOCS®: drugdocs.com
March 3, 2026 at 2:51 PM
🌍 World Obesity Day highlights that 4 billion people may be living with overweight or obesity by 2035.
Addressing obesity requires prevention, equitable care, and evidence-based treatment.
Explore the clinical evidence behind approved obesity therapies on DRUGDOCS®: drugdocs.com
Addressing obesity requires prevention, equitable care, and evidence-based treatment.
Explore the clinical evidence behind approved obesity therapies on DRUGDOCS®: drugdocs.com
Keytruda has gained its first FDA approval in ovarian cancer for PD-L1+ platinum-resistant recurrent disease. Phase 3 data showed reduced risk of progression and death versus control.
Find all the clinical evidence for Keytruda’s 40+ indications at DRUGDOCS® drugdocs.com/drug/Keytruda
Find all the clinical evidence for Keytruda’s 40+ indications at DRUGDOCS® drugdocs.com/drug/Keytruda
February 24, 2026 at 3:40 PM
Keytruda has gained its first FDA approval in ovarian cancer for PD-L1+ platinum-resistant recurrent disease. Phase 3 data showed reduced risk of progression and death versus control.
Find all the clinical evidence for Keytruda’s 40+ indications at DRUGDOCS® drugdocs.com/drug/Keytruda
Find all the clinical evidence for Keytruda’s 40+ indications at DRUGDOCS® drugdocs.com/drug/Keytruda